Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

Immunotargeting of a recurrent AML-specific neoantigen

Nature Cancer volume 4, pages 1403–1405 (2023)Cite this article

Subjects

The development of immunotherapies for acute myeloid leukemia (AML) has been limited by a lack of known tumor-specific targets. A study now shows the feasibility of developing highly sensitive and selective T cell-receptor-based therapies against an HLA-A*02:01-associated peptide derived from a recurrent mutation in a subset of patients with AML.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Targeted analyses identify a TCR reactive to a shared mutant AML-specific antigen.

References

  1. Hofmann, S. et al. J. Clin. Med. 8, 200 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Laumont, C. M. et al. Sci. Transl. Med. 10, eaau5516 (2018).

    Article  CAS  PubMed  Google Scholar 

  3. Apavaloaei, A., Hardy, M., Thibault, P. & Perreault, C. Cancers. 12, 2607 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cancer Genome Atlas Research Network. N. Engl. J. Med. 368, 2059–2074 (2013).

  5. Fennell, K. A., Bell, C. C. & Dawson, M. A. Blood 134, 1891–1901 (2019).

    Article  PubMed  Google Scholar 

  6. Ehx, G. et al. Immunity 54, 737–752 (2021).

    Article  CAS  PubMed  Google Scholar 

  7. Caron, E. et al. Mol. Cell. Proteomics 14, 3105–3117 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Giannakopoulou, E. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00642-8 (2023).

    Article  PubMed  Google Scholar 

  9. Daver, N., Schlenk, R. F., Russell, N. H. & Levis, M. J. Leukemia 33, 299–312 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Marcu, A. et al. J. Immunother. Cancer 9, e002071 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Cameron, B. J. et al. Sci. Transl. Med. 5, 197ra103 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  12. Raman, M. C. C. et al. Sci. Rep. 6, 18851 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Pearlman, A. H. et al. Nat. Cancer 2, 487–497 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. McGranahan, N. et al. Science 351, 1463–1469 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wolf, Y. & Samuels, Y. Clin. Cancer Res. 28, 2994–3001 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Université de Montréal, Montreal, Quebec, Canada

    Anca Apavaloaei & Claude Perreault

Authors
  1. Anca Apavaloaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claude Perreault
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claude Perreault.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Apavaloaei, A., Perreault, C. Immunotargeting of a recurrent AML-specific neoantigen. Nat Cancer 4, 1403–1405 (2023). https://doi.org/10.1038/s43018-023-00634-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00634-8

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer